BioCentury
ARTICLE | Company News

J&J, Watson neurology news

May 17, 2010 7:00 AM UTC

The U.S. Court of Appeals for the Federal Circuit denied an appeal by Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. division to overturn a 2009 ruling by the U.S. District Court for the District of Delaware that found one of two patents for the company's Concerta methylphenidate was invalid and not infringed by Watson's Andrx Corp subsidiary. In 2005, Ortho-McNeil and Alza Corp., which is part of JNJ, filed suit alleging that an ANDA filed by Andrx for a generic version of Concerta infringed Alza's U.S. Patent No. 6,919,373 and 6,930,129. The ANDA contains a paragraph IV certification against the '373 and '129 patents, which both expire Jan. 31, 2018, and covers a method of treating ADD and ADHD. Last March, the court ruled that the '373 patent was invalid and dismissed claims against '129. ...